Sg3 Management, LLC Relmada Therapeutics, Inc. Put Options Transaction History

Sg3 Management, LLC

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $60,480 - $128,520	-27,000 Closed	0 $0
Q3 2022 May 15, 2023	BUY	$18.3 - $37.02 $494,100 - $999,540	27,000 New	27,000 $999,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $292,800 - $592,320	16,000 Added 145.45%	27,000 $1 Million
Q2 2022 Aug 15, 2022	SELL	$16.5 - $30.34 $688,050 - $1.27 Million	-41,700 Reduced 79.13%	11,000 $209,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $881,143 - $1.42 Million	52,700 New	52,700 $1.42 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $83M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.